Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

Journal of Bone Oncology

Volumn 4, Issue 1, 2015, Pages 1-12

  Ségaliny, Aude I ^a,b   Tellez Gabriel, Marta ^a,b   Heymann, Marie Françoise ^a,b,c   Heymann, Dominique ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bone metastasis; Bone sarcoma; Growth factor; Inhibitor; Receptor tyrosine kinase; Therapy

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

BONE CANCER; BONE METASTASIS; ENZYME ACTIVATION; ENZYME STRUCTURE; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84927713594     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2015.01.001     Document Type: Review

References (166)

1. D.L. Garbers, D. Koesling, and G. Schultz Guanylyl cyclase receptors. Mol Biol Cell 5 1994 1 5
2. M. Bhattacharya, A.V. Babwah, and S.S.G. Ferguson Small GTP-binding protein-coupled receptors Biochem Soc Trans 32 2004 1040 1044
3. S. Li, A.H.C. Wong, and F. Liu Ligand-gated ion channel interacting proteins and their role in neuroprotection Front Cell Neurosci 8 2014 125
4. C. Liongue, and A.C. Ward Evolution of class I cytokine receptors BMC Evol Biol 7 2007 120
5. J.A. Langer, E.C. Cutrone, and S. Kotenko The class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions Cytokine Growth Factor Rev 15 2004 33 48
6. W. Liao, J.X. Lin, and W.J. Leonard IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation Curr Opin Immunol 23 2011 598 604
7. F. Blanchard, L. Duplomb, M. Baudhuin, and B. Brounais The dual role of IL-6-type cytokines on bone remodeling and bone tumors Cytokine Growth Factor Rev 20 2009 19 28
8. Bone cancer, primary bone cancers and bone metastases D. Heymann 2nd ed. 2014 Academic Press San Diego, USA
9. D.R. Robins, Y.M. Wu, and S.F. Lin The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
10. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
11. I.T. Arkin Structural aspects of oligomerization taking place between the transmembrane α-helices of bitopic membrane proteins Biochim Biophys Acta 1565 2002 347 363
12. T. Moriki, H. Maruyama, and I.N. Maruyama Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain J Mol Biol 311 2001 1011 1026
13. S.R. Hubbard, and J.H. Till Protein tyrosine kinase structure and function Ann Rev Biochem 69 2000 373 398
14. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
15. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, and J.H. Kim Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787
16. R.A. Bradshaw, R.J. Chalkley, J. Biarc, and A.L. Burlingame Receptor tyrosine kinase signaling mechanisms: devolving TrkA responses with phosphoproteomics Adv Biol Regul 53 2013 87 96
17. S.R. Hubbard Autoinhibitory mechanisms in receptor tyrosine kinases Front Biosci 7 2002 330 340
18. S.R. Hubbard, and W.T. Miller Receptor tyrosine kinases: mechanisms of activation and signaling Curr Opin Cell Biol 19 2007 117 123
19. Y. Liu, and L.R. Rohrschneider The gift of gab FEBS Lett 515 2002 1 7
20. C. Choudhary, and M. Mann Decoding signalling networks by mass spectrometry-based proteomics Nat Rev Mol Cell Biol 11 2010 427 439
21. B. Cseh, E. Doma, and M. Baccarini "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway FEBS Lett 588 2014 2398 2406
22. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 66 2012 105 143
23. M. Raman, W. Chen, and M.H. Cobb Differential regulation and properties of MAPKs Oncogene 26 2007 3100 3112
24. M. Cargnello, and P.P. et Roux Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases Microbiol Mol Biol Rev 75 2011 50 83
25. G. Song, G. Ouyang, and S. Bao The activation of Akt/PKB signaling pathway and cell survival J Cell Mol Med 9 2005 59 71
26. R. Ralston, and J.M. Bishop The product of the protooncogene c-Src is modified during the cellular response to platelet-derived growth factor Proc Natl Acad Sci USA 82 1985 7845 7849
27. P.A. Bromann, H. Korkaya, and S.A. Courtneidge The interplay between Src family kinases and receptor tyrosine kinases Oncogene 23 2004 7957 7968
28. J.S. Biscardi, M.C. Maa, D.A. Tice, M.E. Cox, T.H. Leu, and S.J. Parsons C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function J Biol Chem 274 1999 8335 8343
29. L. Moro, L. Dolce, S. Cabodi, E. Bergatto, E.B. Erba, and M. Smerigli Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines J Biol Chem 277 2002 9405 9414
30. T. Goi, M. Shipitsin, Z. Lu, D.A. Foster, S.G. Klinz, and L.A. Feig An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity EMBO J 19 2000 623 630
31. T. Livio, A. Berlotti, and P.M. Comoglio MET signaling: principles and functions in development, organ regeneration and cancer Nat Rev Mol Cell Biol 11 2010 834 848
32. M. Freeman Feedback control of intercellular signaling in development Nature 408 2000 313 319
33. I. Amit, A. Citri, T. Shay, Y. Lu, M. Katz, and F. Zhang A module of negative feedback regulators defines growth factor signaling Nat Genet 39 2007 503 512
34. S.D. Santos, P.J. Verveer, and P.I. Bastiaens Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate Nat Cell Biol 9 2007 324 330
35. I. Dikic, and S. Giordano Negative receptor signalling Curr Opin Cell Biol 15 2003 128 135
36. M.D. Marmor, and Y. Yarden Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases Oncogene 23 2004 2057 2070
37. X. Jiang, F. Huang, A. Marusyk, and A. Sorkin Grb2 regulates internalization of EGF receptors through clathrin-coated pits Mol Biol Cell 14 2003 858 870
38. Z. Lu, G. Jiang, P. Jensen, and T. Hunter Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase Mol Cell Biol 21 2001 4016 4031
39. ∗ Oncogene 16 1998 843 851
40. S. Meshinchi, and F.R. Appelbaum Structural and functional alterations of FLT3 in acute myeloid leukemia Clin Cancer Res 15 2009 4263 4269
41. C.R. Antonescu The GIST paradigm: lessons for other kinase-driven cancers J Pathol 223 2011 251 261
42. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
43. R. Bose, S.M. Kavuri, A.C. Searleman, W. Shen, D. Shen, and D.C. Koboldt Activating HER2 mutations in HER2 gene amplification negative breast cancer Cancer Discov 3 2013 224 237
44. H. Nakajima, Y. Ishikawa, M. Furuya, T. Sano, Y. Ohno, and J. Horiguchi Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer Breast Cancer 21 2014 66 74
45. C. Peraldo-Neia, G. Migliardi, M. Mello-Grand, F. Montemurro, R. Segir, and Y. Pignochino Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer BMC Cancer 11 2011 31
46. M. Fu, W. Zhang, L. Shan, J. Song, D. Shang, and J. Ying Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa) Virchows Arch 464 2014 575 581
47. P.J. Marie Signaling pathways affecting skeletal health Curr Osteoporos Rep 10 2012 190 198
48. P.J. Marie Fibroblast growth factor signaling controlling bone formation: an update Gene 498 2012 1 4
49. J. Dai, and A.B. Rabie VEGF: an essential mediator of both angiogenesis and endochondral ossification J Dent Res 86 2007 937 950
50. H. Al-Kharobi, R. El-Gendy, D.A. Devine, and J. Beattie The role of the insulin like growth factor (IGF) axis in osteogenic and odontogenic differentiation Cell Mol Life Sci 71 2014 1469 1476
51. N.A. Sims, and T.J. Martin Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit BoneKEy Rep 3 2014 481
52. D. Heymann, J. Guicheux, F. Gouin, N. Passuti, and G. Daculsi Cytokines growth factors and osteoclasts Cytokine 10 1998 155 168
53. C.E. Clarkin, and L.C. Gerstenfeld VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct 31 2013 1 11
54. J.L. Crane, and X. Cao Function of matrix IGF-1 in coupling bone resorption and formation J Mol Med (Berl) 92 2014 107 115
55. N.R. Bao, M. Lu, F.W. Bin, Z.Y. Chang, J. Meng, and L.W. Zhou Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells Int J Clin Exp Pathol 6 2013 2082 2091
56. S. O'Sullivan, J.M. Lin, M. Watson, K. Callon, P.C. Tong, and D. Naot The skeletal effects of the tyrosine kinase inhibitor nilotinib Bone 49 2011 281 289
57. J. Pinski, A. Weeraratna, A.R. Uzgare, J.T. Arnold, and S.R. Denmeade Isaacs JT.Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts Cancer Res 62 2002 986 989
58. Z. Duan, E. Choy, D. Harmon, C. Yang, K. Ryu, and J. Schwab Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Mol Cancer Ther 8 2009 2122 2130
59. K. Vandyke, S. Fitter, A.L. Dewar, T.P. Hughes, and A.C. Zannettino Dysregulation of bone remodeling by imatinib mesylate Blood 115 4 2010 766 774
60. B. Gobin, G. Moriceau, B. Ory, C. Charrier, R. Brion, and F. Blanchard Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models PLoS One 9 2014 e90795
61. I. El Hajj Dib, M. Gallet, R. Mentaverri, N. Sévenet, M. Brazier, and S. Kamel Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity Eur J Pharmacol 551 2006 27 33
62. E. Rimondi, P. Secchiero, E. Melloni, V. Grill, and G. Zauli Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1 Invest New Drugs 31 2013 780 786
63. K. Vandyke, A.L. Dewar, P. Diamond, S. Fitter, C.G. Schultz, and N.A. Sims The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo J Bone Miner Res 5 2010 1759 1770
64. A. Garcia-Gomez, E.M. Ocio, E. Crusoe, C. Santamaria, P. Hernández-Campo, and J.F. Blanco Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects PLoS One 7 2012 e34914
65. D. Heymann, and F. Redini Bone sarcomas: pathogenesis and new therapeutic approaches IBMS BoneKEy 8 2011 402 414
66. D. Heymann, and F. Redini Targeted therapies for bone sarcomas BoneKEy Rep 2 2013 378
67. N. Gaspar, A. Di Giannatale, B. Geoerger, F. Redini, N. Corradini, and N. Enz-Werle Bone sarcomas: from biology to targeted therapies Sarcoma 2012 2012 301975
68. A.N. Rettew, P.J. Getty, and E.M. Greenfield Receptor tyrosine kinases in osteosarcoma: not just the usual suspects Adv Exp Med Biol 804 2014 47 66
69. E.C. McGary, K. Weber, L. Mills, M. Doucet, V. Lewis, and D.C. Lev Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 Clin Cancer Res 8 2002 3584 3591
70. A.K. Ikeda, D.R. Judelson, N. Federman, K.B. Glaser, E.M. Landaw, and C.T. Denny ABT-869 inhibits the proliferation of Ewing sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways Mol Cancer Ther 9 2010 653 660
71. R. Chugh, J.K. Wathen, R.G. Maki, R.S. Benjamin, S.R. Patel, and P.A. Meyers Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model J Clin Oncol 27 2009 3148 3153
72. J. Chao, G.T. Budd, P. Chu, P. Frankel, D. Garcia, and M. Junqueira Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumours and desmoplastic small round cell tumours Anticancer Res 30 2010 547 552
73. M. Bond, M.L. Bernstein, A. Pappo, K.R. Schultz, M. Krailo, and S.M. Blaney A phase II study of imatinib mesylate in children with refractory or relapsed solid tumours: a Children's Oncology Group study Pediatr Blood Cancer 50 2008 254 258
74. I. Gonzalez, E.J. Andreu, A. Panizo, S. Inoges, A. Fontalba, and J.L. Fernandez-Luna Imatinib inhibits proliferation of Ewing tumour cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis Clin Cancer Res 10 2004 751 761
75. F. Timeus, N. Crescenzio, A. Fandi, A. Doria, L. Foglia, and L. Cordero di Montezemolo In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines Oncol Rep 19 2008 353 359
76. P. Hingorani, W. Zhang, R. Gorlick, and E.A. Kolb Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo Clin Cancer Res 15 2009 3416 3422
77. R. Aplenc, S.M. Blaney, L.C. Strauss, F.M. Balis, S. Shusterman, and A.M. Ingle Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium J Clin Oncol 29 2011 839 844
78. J.M. Maris, J. Courtright, P.J. Houghton, C.L. Morton, E.A. Kolb, and R. Lock Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program Pediatr Blood Cancer 51 2008 42 48
79. S.G. Dubois, S. Shusterman, A.M. Ingle, C.H. Ahern, J.M. Reid, and B. Wu Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumours: a children's oncology group study Clin Cancer Res 17 2011 5113 5122
80. S.T. Keir, C.L. Morton, J. Wu, R.T. Kurmasheva, P.J. Houghton, and M.A. Smith Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program Pediatr Blood Cancer 59 2012 586 588
81. J.L. Glade Bender, A. Lee, J.M. Reid, S. Baruchel, T. Roberts, and S.D. Voss Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a childrens oncology group phase I consortium report J Clin Oncol 31 2013 3034 3043
82. S. Kumar, R.B. Mokhtari, R. Sheikh, B. Wu, L. Zhang, and P. Xu Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumour Clin Cancer Res 17 2011 5656 5667
83. Y. Pignochino, G. Grignani, G. Cavalloni, M. Motta, M. Tapparo, and S. Bruno Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Mol Cancer 8 2009 118
84. F. Navid, S.D. Baker, M.B. McCarville, C.F. Stewart, C.A. Billups, and J. Wu Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors Clin Cancer Res 19 2013 236 246
85. G. Grignani, E. Palmerini, P. Dileo, S.D. Asaftei, L. D'Ambrosio, and Y. Pignochino A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Ann Oncol 23 2012 508 516
86. J. Han, R. Tian, B. Yong, C. Luo, P. Tan, and J. Shen Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients Biochem Biophys Res Commun 435 2013 493 500
87. A.N. Rettew, P.J. Getty, and E.M. Greenfield Receptor tyrosine kinases in osteosarcoma: not just the usual suspects Adv Exp Med Biol 804 2014 47 66
88. Y. Zhang, Y.J. Tang, Y. Man, F. Pan, Z.H. Li, and L.S. Jia Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis Int J Immunopathol Pharmacol 26 2013 179 188
89. E.D. Fleuren, M.H. Hillebrandt-Roeffen, U.E. Flucke, D.M. Te Loo, O.C. Boerman, and W.T. van der Graaf The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma Oncotarget 5 2014 12753 12768
90. E.D. Fleuren, M.H. Roeffen, W.P. Leenders, U.E. Flucke, M. Vlenterie, and H.W. Schreuder Expression and clinical relevance of MET and ALK in Ewing sarcomas Int J Cancer 133 2013 427 436
91. E.R. Sampson, B.A. Martin, A.E. Morris, C. Xie, E.M. Schwarz, and R.J. OKeefe The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model J Bone Miner Res 26 2011 1283 1294
92. R. Fritsche-Guenther, A. Noske, U. Ungethüm, R.J. Kuban, P.M. Schlag, and P.U. Tunn De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway Histopathology 57 2010 836 850
93. K. Mstuo, and N. Otaki Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases Cell Adhes Migr 6 2012 148 156
94. J. Posthumadeboer, S.R. Piersma, T.V. Pham, P.W. van Egmond, J.C. Knol, and A.M. Cleton-Jansen Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery Br J Cancer 109 2013 2142 2154
95. M.L. Kuijjer, E.F. Peterse, B.E. van den Akker, I.H. Briaire-de Bruijn, M. Serra, and L.A. Meza-Zepeda IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma BMC Cancer 13 2013 245
96. Y. Cao, M. Roth, S. Piperdi, K. Montoya, R. Sowers, and P. Rao Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma PLoS One 9 2014 e106249
97. J.A. Lee, Y. Ko, D.H. Kim, J.S. Lim, C.B. Kong, and W.H. Cho Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat 44 2012 202 209
98. J. Gill, D. Geller, and R. Gorlick HER-2 involvement in osteosarcoma Adv Exp Med Biol 804 2014 161 177
99. D. Ebb, P. Meyers, H. Grier, M. Bernstein, R. Gorlick, and S.E. Lipshultz Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the childrens oncology group J Clin Oncol 30 2012 2545 2551
100. M.L. Macheda, and S.A. Stacker Importance of Wnt signaling in the tumour stroma microenvironment Curr Cancer Drug Targets 8 2008 454 465
101. L. Truitt, and A. Freywald Dancing with the dead: Eph receptors and their kinase-null partners Biochem Cell Biol 89 2011 115 129
102. P. Clézardin Pathophysiology of bone metastases and new molecular targets involved in bone remodelling Bull Cancer 100 2013 1083 1091
103. H. Uehara, S.J. Kim, T. Karashima, D.L. Shepherd, D. Fan, and R. Tsan Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases J Natl Cancer Inst 95 2003 458 470
104. S.J. Kim, H. Uehara, S. Yazici, J.E. Busby, T. Nakamura, and J. He Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer J Natl Cancer Inst 98 2006 783 793
105. N.M. Tiffany, E.M. Wersinger, M. Garzotto, and T.M. Beer Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer Urology 63 2004 934 939
106. P. Mathew, P.F. Thall, D. Jones, C. Perez, C. Bucana, and P. Troncoso Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer J Clin Oncol 22 2004 3323 3329
107. P. Mathew, P.F. Thall, C.D. Bucana, W.K. Oh, M.J. Morris, and D.M. Jones Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases Clin Cancer Res 13 2007 5816 5824
108. Y. Liu, M. Karaca, Z. Zhang, D. Gioeli, H.S. Earp, and Y.E. Whang Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases Oncogene 29 2010 3208 3216
109. J.C. Araujo, A. Poblenz, P. Corn, N.U. Parikh, M.W. Starbuck, and J.T. Thompson Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation Cancer Biol Ther 8 2009 2153 2159
110. T. Koreckij, H. Nguyen, L.G. Brown, E.Y. Yu, R.L. Vessella, and E. Corey Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis Br J Cancer 101 2009 263 268
111. S. Takahashi, M. Miyazaki, I. Okamoto, Y. Ito, K. Ueda, and T. Seriu Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors Cancer Sci 102 2011 2058 2064
112. E.Y. Yu, C. Massard, M.E. Gross, M.A. Carducci, S. Culine, and G. Hudes Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer Urology 77 2011 1166 1171
113. E.Y. Yu, G. Wilding, E. Posadas, M. Gross, S. Culine, and C. Massard Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7421 7428
114. J.C. Araujo, G.C. Trudel, F. Saad, A.J. Armstrong, E.Y. Yu, and J. Bellmunt Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial Lancet Oncol 14 2013 1307 1316
115. P. Zwolak, P. Jasinski, K. Terai, N.J. Gallus, M.E. Ericson, and D.R. Clohisy Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone Eur J Cancer 44 2008 2506 2517
116. G. Sonpavde, P.O. Periman, D. Bernold, D. Weckstein, M.T. Fleming, and M.D. Galsky Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2010 319 324
117. M.D. Michaelson, S. Oudard, Y.C. Ou, L. Sengeløv, F. Saad, and N. Houede Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer J Clin Oncol 32 2014 76 82
118. T. Bachelot, J.A. Garcia-Saenz, S. Verma, M. Gutierrez, X. Pivot, and M.F. Kozloff Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study BMC Cancer 14 2014 166
119. B. Beuselinck, S. Oudard, O. Rixe, P. Wolter, A. Blesius, and J. Ayllon Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib Ann Oncol 22 2011 794 800
120. D. Keizman, M. Ish-Shalom, R. Pili, H. Hammers, M.A. Eisenberger, and V. Sinibaldi Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma Eur J Cancer 48 2012 1031 1037
121. M. Merz, D. Komljenovic, S. Zwick, W. Semmler, and T. Bäuerle Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases Eur J Cancer 47 2011 277 286
122. W.L. Dahut, C. Scripture, E. Posadas, L. Jain, J.L. Gulley, and P.M. Arlen A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 2008 209 214
123. J.B. Aragon-Ching, L. Jain, J.L. Gulley, P.M. Arlen, J.J. Wright, and S.M. Steinberg Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer BJU Int 103 2009 1636 1640
124. A. Sciarra, A.M. Autran Gomez, A. Gentilucci, U. Parente, S. Salciccia, and V. Gentile Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report Eur Urol 52 2007 597 599
125. P.A. Humphrey, X. Zhu, R. Zarnegar, P.E. Swanson, T.L. Ratliff, and R.T. Vollmer Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma Am J Pathol 147 1995 386 396
126. L.L. Pisters, P. Troncoso, H.E. Zhau, W. Li, A.C. von Eschenbach, and L.W. Chung c-met proto-oncogene expression in benign and malignant human prostate tissues J Urol 154 1995 293 298
127. J. Nagy, G.W. Curry, K.J. Hillan, I.C. McKay, E. Mallon, and A.D. Purushotham Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer Surg Oncol 5 1996 15 21
128. A.B. Tuck, M. Park, E.E. Sterns, A. Boag, and B.E. Elliott Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma Am J Pathol 148 1996 225 232
129. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 12 2003 915 925
130. M.G. Ponzo, R. Lesurf, S. Petkiewicz, F.P. OMalley, D. Pinnaduwage, and I.L. Andrulis Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer Proc Natl Acad Sci USA 106 2009 12903 12908
131. S. Previdi, F. Scolari, R. Chilà, F. Ricci, G. Abbadessa, and M. Broggini Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model PLoS One 8 2013 e79101
132. T.J. Graham, G. Box, N. Tunariu, M. Crespo, T.J. Spinks, S. Miranda, et al., Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib, J Natl Cancer Inst, in press
133. R.J. Lee, P.J. Saylor, M.D. Michaelson, S.M. Rothenberg, M.E. Smas, and D.T. Miyamoto A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases Clin Cancer Res 19 2013 3088 3094
134. M.R. Smith, C.J. Sweeney, M.R. Corn Smith, C.J. Sweeney, P.G. Corn, and D.E. Rathkopf Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study J Clin Oncol 32 2014 3391 3399
135. D.C. Smith, M.R. Smith, C. Sweeney, A.A. Elfiky, C. Logothetis, and P.G. Corn Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
136. E. Basch, K.A. Autio, M.R. Smith, A.V. Bennett, A.L. Weitzman, C. Scheffold, et al., Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort, Eur Urol, in press
137. S. Previdi, F. Scolari, R. Chilà, F. Ricci, G. Abbadessa, and M. Broggini Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model PLoS One 8 2013 e79101
138. S. Previdi, G. Abbadessa, F. Dalò, D.S. France, and M. Broggini Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown Mol Cancer Ther 11 2012 214 223
139. J.J. Yin, L. Zhang, J. Munasinghe, R.I. Linnoila, and K. Kelly Ceranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer Cancer Res 70 2010 8662 8673
140. C.J. Ryan, W.M. Stadler, B. Roth, D. Hutcheon, S. Conry, and T. Puchalski Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) Invest New Drugs 25 5 2007 445 451
141. R. Bachelier, C.B. Confavreux, O. Peyruchaud, M. Croset, D. Goehrig, and G. van der Pluijm Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis Int J Cancer 135 2014 1319 1329
142. K. Furugaki, Y. Moriya, T. Iwai, K. Yorozu, M. Yanagisawa, and K. Kondoh Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292 Clin Exp Metastasis 28 2011 649 659
143. C. Nabhan, T.M. Lestingi, A. Galvez, K. Tolzien, S.K. Kelby, and D. Tsarwhas Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial Urology 74 2009 665 671
144. M. Gross, C. Higano, A. Pantuck, O. Castellanos, E. Green, and K. Nguyen A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer BMC Cancer 7 2007 142
145. A. DAlessio, A. De Luca, M.R. Maiello, L. Lamura, A.M. Rachiglio, and M. Napolitano Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells Breast Cancer Res Treat 123 2010 387 396
146. C. Borghese, L. Cattaruzza, E. Pivetta, N. Normanno, A. De Luca, and M. Mazzucato Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity J Cell Biochem 114 2013 1135 1144
147. A. Sgambato, A. Camerini, B. Faraglia, R. Ardito, G. Bianchino, and D. Spada Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (Iressa) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells J Cell Physiol 201 2004 97 105
148. C. Pezaro, M.A. Rosenthal, H. Gurney, I.D. Davis, C. Underhill, and M.J. Boyer An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer Am J Clin Oncol 32 2009 338 341
149. F. Boccardo, A. Rubagotti, G. Conti, M. Battaglia, G. Cruciani, and A. Manganelli Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial Oncology 74 2008 223 228
150. M. Salzberg, C. Rochlitz, R. Morant, G. Thalmann, A. Pedrazzini, and E. Roggero An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer Onkologie 30 2007 355 360
151. G. Somlo, C.L. Martel, S.K. Lau, P. Frankel, C. Ruel, and L. Gu A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer Breast Cancer Res Treat 131 2012 899 906
152. R.W. Carlson, A. ONeill, T. Vidaurre, H.L. Gomez, S.S. Badve, and G.W. Sledge A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer Breast Cancer Res Treat 133 2012 1049 1056
153. C.K. Osborne, P. Neven, L.Y. Dirix, J.R. Mackey, J. Robert, and C. Underhill Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Clin Cancer Res 17 2011 1147 1159
154. M. Cristofanilli, V. Valero, A. Mangalik, M. Royce, I. Rabinowitz, and F.P. Arena Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer Clin Cancer Res 16 2010 1904 1914
155. Y.E. Whang, A.J. Armstrong, W.K. Rathmell, P.A. Godley, W.Y. Kim, and R.S. Pruthi A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer Urol Oncol 31 2013 82 86
156. M. Pircher, B. Mlineritsch, M.A. Fridrik, C. Dittrich, A. Lang, and E. Petru Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial Anticancer Res 35 2015 517 521
157. S.S. Sridhar, S.J. Hotte, J.L. Chin, G.R. Hudes, R. Gregg, and J. Trachtenberg A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer Am J Clin Oncol 33 2010 609 613
158. A.A. Azad, E.K. Beardsley, S.J. Hotte, S.L. Ellard, L. Klotz, and J. Chin A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer Invest New Drugs 32 2014 746 752
159. M.J. Clemons, B. Cochrane, G.R. Pond, N. Califaretti, S.K. Chia, and R.A. Dent Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study Breast Cancer Res Treat 146 2014 153 162
160. X. Wan, P.G. Corn, J. Yang, N. Palanisamy, M.W. Starbuck, and E. Efstathiou Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases Sci Transl Med 6 2014 122 252
161. S. Vallo, J. Mani, M. Stastny, J. Makarević, E. Juengel, and I. Tsaur The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258 Invest New Drugs 31 2013 265 272
162. H.M. Nguyen, N. Ruppender, X. Zhang, L.G. Brown, T.S. Gross, and C. Morrissey Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling PLoS One 8 2013 e78881
163. R.J. Lee, and M.R. Smith Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Clin Cancer Res 20 2014 525 527
164. M.B. Meads, L.A. Hazlehurst, and W.S. Dalton The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance Clin Cancer Res 14 2008 2519 2526
165. E. David, F. Blanchard, M.F. Heymann, G. De Pinieux, F. Gouin, and F. Rédini The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets Sarcoma 2011 2011 932451
166. J.C. Trent, and M.P. Subramanian Managing GIST in the imatinib era: optimization of adjuvant therapy Expert Rev Anticancer Ther 14 2014 1445 1459